|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CLDND1 |
Gene summary for CLDND1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CLDND1 | Gene ID | 56650 |
| Gene name | claudin domain containing 1 | |
| Gene Alias | C3orf4 | |
| Cytomap | 3q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9NY35 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 56650 | CLDND1 | Tumor | Human | Cervix | CC | 1.96e-08 | 4.18e-01 | 0.1241 |
| 56650 | CLDND1 | sample3 | Human | Cervix | CC | 2.88e-24 | 5.81e-01 | 0.1387 |
| 56650 | CLDND1 | L1 | Human | Cervix | CC | 6.80e-04 | 3.35e-01 | 0.0802 |
| 56650 | CLDND1 | T1 | Human | Cervix | CC | 8.54e-05 | 2.87e-01 | 0.0918 |
| 56650 | CLDND1 | T3 | Human | Cervix | CC | 3.59e-19 | 5.73e-01 | 0.1389 |
| 56650 | CLDND1 | LZE4T | Human | Esophagus | ESCC | 7.33e-25 | 9.39e-01 | 0.0811 |
| 56650 | CLDND1 | LZE7T | Human | Esophagus | ESCC | 3.56e-09 | 9.97e-01 | 0.0667 |
| 56650 | CLDND1 | LZE8T | Human | Esophagus | ESCC | 2.95e-18 | 8.71e-01 | 0.067 |
| 56650 | CLDND1 | LZE20T | Human | Esophagus | ESCC | 3.73e-04 | 2.56e-01 | 0.0662 |
| 56650 | CLDND1 | LZE22T | Human | Esophagus | ESCC | 1.11e-02 | 4.77e-01 | 0.068 |
| 56650 | CLDND1 | LZE24T | Human | Esophagus | ESCC | 2.04e-28 | 1.07e+00 | 0.0596 |
| 56650 | CLDND1 | LZE6T | Human | Esophagus | ESCC | 7.72e-08 | 7.02e-01 | 0.0845 |
| 56650 | CLDND1 | P1T-E | Human | Esophagus | ESCC | 4.97e-13 | 5.89e-01 | 0.0875 |
| 56650 | CLDND1 | P2T-E | Human | Esophagus | ESCC | 6.36e-31 | 4.43e-01 | 0.1177 |
| 56650 | CLDND1 | P4T-E | Human | Esophagus | ESCC | 2.40e-30 | 7.61e-01 | 0.1323 |
| 56650 | CLDND1 | P5T-E | Human | Esophagus | ESCC | 4.29e-69 | 1.56e+00 | 0.1327 |
| 56650 | CLDND1 | P8T-E | Human | Esophagus | ESCC | 5.59e-56 | 1.12e+00 | 0.0889 |
| 56650 | CLDND1 | P9T-E | Human | Esophagus | ESCC | 3.70e-77 | 2.95e+00 | 0.1131 |
| 56650 | CLDND1 | P10T-E | Human | Esophagus | ESCC | 2.84e-64 | 1.35e+00 | 0.116 |
| 56650 | CLDND1 | P11T-E | Human | Esophagus | ESCC | 2.43e-18 | 5.60e-01 | 0.1426 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CLDND1 | SNV | Missense_Mutation | rs754278234 | c.266N>G | p.Asp89Gly | p.D89G | protein_coding | deleterious(0.04) | possibly_damaging(0.897) | TCGA-D8-A1JB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| CLDND1 | SNV | Missense_Mutation | c.397N>T | p.Thr133Ser | p.T133S | protein_coding | tolerated(0.62) | benign(0.006) | TCGA-E2-A15M-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| CLDND1 | SNV | Missense_Mutation | c.604N>A | p.Leu202Ile | p.L202I | protein_coding | tolerated(0.09) | possibly_damaging(0.519) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CLDND1 | SNV | Missense_Mutation | c.363N>T | p.Glu121Asp | p.E121D | protein_coding | tolerated(0.44) | benign(0.009) | TCGA-A6-6138-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
| CLDND1 | SNV | Missense_Mutation | novel | c.802N>G | p.Thr268Ala | p.T268A | protein_coding | tolerated(0.11) | possibly_damaging(0.607) | TCGA-AA-A01K-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folinic | CR | |
| CLDND1 | SNV | Missense_Mutation | rs748541120 | c.587N>T | p.Thr196Met | p.T196M | protein_coding | deleterious(0.01) | probably_damaging(0.958) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CLDND1 | SNV | Missense_Mutation | rs142343871 | c.563N>A | p.Arg188Gln | p.R188Q | protein_coding | tolerated(0.09) | benign(0.022) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| CLDND1 | SNV | Missense_Mutation | novel | c.252N>C | p.Glu84Asp | p.E84D | protein_coding | deleterious(0.04) | benign(0.398) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| CLDND1 | SNV | Missense_Mutation | rs766779480 | c.278N>A | p.Arg93Gln | p.R93Q | protein_coding | tolerated(0.26) | benign(0.031) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
| CLDND1 | SNV | Missense_Mutation | novel | c.215N>T | p.Ser72Ile | p.S72I | protein_coding | tolerated(0.06) | benign(0.003) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |